Phase 2 Study with TTI-622 and TTI-621 in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)


About this study

The purpose of ths study is to find out more about the side effects of two new drug combinations for lymphoma, TTI-621 and pembrolizumab and TTI-622 and pembrolizumab, and what doses of TTI-621 and TTI-622 are safe for people to take.  In addition, we want to learn if the drug combinations help your cancer.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Documented CD20+ mature B-cell neoplasm according to WHO classification (Swerdlow et al., 2016) as one of the following:
    • Diffuse large B-cell lymphoma NOS including:
    • Transformed lymphoma;
    • Richter’s transformation;
    • Germinal center B-cell type;
    • Activated B-cell type;
    • High-grade B-cell lymphoma (HGBCL), NOS);
    • Primary mediastinal (thymic) large B-cell lymphoma.
  • Patients with “double-hit” or “triple-hit” DLBCL (technically as HGBCL, with MYC and BCL2 and/or BCL6 rearrangements).
  • Follicular lymphoma 3B.
  • T-cell/histiocyte-rich large B cell lymphoma.
  • Large B-cell lymphoma with IRF4 rearrangement.
  • Primary cutaneous DLBCL, leg type.
  • EBV positive DLBCL, NOS.
  • DLBCL associated with chronic inflammation.
  • Intravascular large B-cell lymphoma.
  • ALK positive large B-cell lymphoma.
    • Relapsed, progressive and/or refractory disease (Cheson et al., 2007) following treatment with an anti-CD20 monoclonal antibody (e.g., rituximab)  in combination with chemotherapy
      • Measurable disease as defined below: 
      • Fluorodeoxyglucose (FDG)-avid lymphomas: Measurable disease with computerized tomography (CT) (or magnetic resonance imaging [MRI]) scan with involvement of 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis > 1.0 cm (or 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis ≥ 1.0 cm) AND FDG positron emission tomography (PET) scan that demonstrates positive lesion(s) compatible with CT (or MRI) defined anatomical tumor sites.
  • FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with involvement of 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis > 1.0 cm or 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis ≥ 1.0 cm.
  • ECOG Performance Status (PS) 0 or 1.
  • ≥ 4 weeks from last dose of anti-CD20 targeting therapy.      
  • ≥ 12 weeks post CAR T-cell therapy.
  • Resolution of all adverse events due to prior therapy to ≤ Grade 1 or baseline. NOTE: Patients with ≤ Grade 2 neuropathy may be eligible. Patients with endocrine-related AEs Grade ≤ 2 requiring treatment or hormone replacement may be eligible.  investigator
  • If receiving glucocorticoid treatment at screening, treatment must be tapered down and administered with a maximum of 10 mg daily in the last 14 days prior to registration.
  • The following laboratory values obtained ≤ 7 days prior to registration:
    • Absolute neutrophil count (ANC) ≥ 500/mm^3; growth factor support allowed in case of bone marrow involvement;
    • Absolute lymphocyte count  ≥200/mm^3;
    • Platelet count ≥75,000/mm3;
    • Hemoglobin ≥ 8.0 g/dL;
    • INR or PTT/aPTT ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants;
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN), unless due to Gilbert’s disease (direct bili ≤ ULN);
    • Aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 2.5 x ULN;
    • Calculated creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula below:
    • Cockcroft-Gault Equation:
      • Creatinine clearance for males =    (140 - age) (weight in kg) / (72) (serum creatinine in mg/dL);
      • Creatinine clearance for females = (140 - age) (weight in kg) (0.85) / (72)(serum creatinine in mg/dL).
  • Provide informed written consent.
  • Negative pregnancy test done ≤ 3 days prior to registration, for persons of childbearing potential only.
  • Female of childbearing must agree to use a highly effective method of contraception during the treatment and for 120 days after the last dose of study treatment.
  • Male participants with female partners of childbearing potential must agree to refrain from donating sperm and one of the conception methods as described in Appendix V during the treatment and for 120 days after last dose study treatment.
  • Willing to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study).
  • Willing to provide mandatory tissue and blood samples for correlative research purposes.

Exclusion Criteria:

  • Primary ce ntral nervous system (CNS) lymphoma or known CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan (brain) and, if clinically indicated, by lu
  • Known past or current malignancy other than inclusion diagnosis, except for:
    • Cervical carcinoma of Stage 1B or less;
    • Non-invasive basal cell or squamous cell skin carcinoma;
    • Non-invasive, superficial bladder cancer;
    • Prostate cancer with a current PSA level < 0.1 ng/mL;
    • Any curable cancer with a complete response (CR) of > 2 years duration.
  • Received < 2 prior systemic anti-cancer therapy including investigational agents ≤ 4 weeks or ≤5 half-lives, whichever is shorter, prior to registration.
  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) ≤ 4 weeks  prior to registration.
  • Known clinically significant cardiac disease, including:
    • Onset of unstable angina pectoris within 6 months of signing ICF;
    • Acute myocardial infarction within 6 months of signing ICF;
    • Congestive heart failure (grade III or IV as classified by the New York Heart Association and/or known decrease ejection fraction of < 45%).
  • Chronic ongoing infectious diseases (except hepatitis B or hepatitis C) requiring treatment (excluding prophylactic treatment) at the time of enrollment or ≤ the previous 2 weeks.
  • Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy or primary immunodeficiency disorder. Low-dose steroids (≤10 mg daily of prednisone equivalent) is allowed.
  • Seizure disorder requiring therapy (such as steroids or anti-epileptics).
  • Autologous HSCT ≤ 100 days prior or any prior allogeneic HSCT or solid organ transplantation.
  • Known human immunodeficiency virus (HIV) infection.
  • Exposed to live or live attenuated vaccine ≤ 4 weeks prior to registration.
  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
    • Pregnant persons;
    • Nursing persons;
    • Persons of childbearing potential who are unwilling to employ adequate contraception.
  • Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • Uncontrolled intercurrent illness including, but not limited to:
    • ongoing or active infection;
    • uncontrolled infection requiring ongoing antibiotics;
    • symptomatic congestive heart failure;
    • unstable angina pectoris;
    • cardiac arrhythmia;
    • or psychiatric illness/social situations that would limit compliance with study requirements;
    • known substance abuse disorder.
  • Known hypersensitivity to pembrolizumab.
  • Major surgery other than diagnostic surgery ≤ 4 weeks prior to registration.
  • Prior radiation therapy ≤ 2 weeks prior to registration or who has not recovered from all  radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
    • Note:  A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
  • Active autoimmune disease such as Crohn’s disease, rheumatoid arthritis, Sjogren’s disease, systemic lupus erythematosus, or similar conditions requiring systemic treatment ≤ the past 3 months or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past.
    • Vitiligo or resolved childhood asthma/atopy;
    • Intermittent use of bronchodilators or local steroid injections;
    • Hypothyroidism stable on hormone replacement;
    • Diabetes stable with current management;
    • History of positive Coombs test but no evidence of hemolysis;
    • Psoriasis not requiring systemic treatment;
    • Conditions not expected to recur in the absence of an external trigger.
  • Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.
  • Prior anti CD47 therapy.
  • Active use of anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis.
  • There will be no restriction for daily aspirin < 81mg daily.
  • Co-morbid systemic illnesses  or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

Eligibility last updated 6/24/22. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Ansell, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions